 |
|
|
| |
AI-based histologic measurement of NASH (AIM-NASH):
A drug development tool for assessing clinical trial endpoints
|
| |
| |
EASL 2021, 23-26 June
Oscar Carrasco-Zevallos1, Amaro Taylor1, Harsha Pokkalla1, Maryam Pouryahya1, Charles Biddle-Snead1, Ling Han2, Ryan Huss2, Dinkar Juyal1, Zahil Shanis1, Aryan Pedawi1, Quang Le1, Kenneth Leidal1, Victoria Mountain1, Sara Hoffman1, Jackie Honerlaw1, Murray Resnick1, Rohit Loomba3, Arun Sanyal4, Chuhan Chung2, Robert Myers2, Michael Montalto1, Andrew Beck1, Ilan Wapinski1, Katy Wack1
1PathAI, Boston, MA, USA; 2Gilead Sciences, Inc., Foster City, CA, USA; 3University of California at San Diego, CA, USA; 4Virginia Commonwealth University, School of Medicine, Richmond, VA, USA
|
| |
|
|
|
|
|
